Literature DB >> 30671660

Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.

Claudio Cerchione1,2, Amalia De Renzo3, Davide Nappi3, Maria Di Perna3, Roberta Della Pepa3, Novella Pugliese3, Lucio Catalano3, Fabrizio Pane3, Marco Picardi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30671660     DOI： 10.1007/s00520-019-4651-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  9 in total

Review 1.  Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma.

Authors:  Lodovico Balducci; Lazzaro Repetto
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

2.  Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Authors:  Patrizia Mondello; Normann Steiner; Wolfgang Willenbacher; Claudio Cerchione; Davide Nappi; Endri Mauro; Simone Ferrero; Salvatore Cuzzocrea; Michael Mian
Journal:  Oncologist       Date:  2018-01-09

3.  Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience.

Authors:  Claudio Cerchione; Lucio Catalano; Anna Emanuele Pareto; Marco Picardi; Fabrizio Pane
Journal:  Support Care Cancer       Date:  2014-10-24       Impact factor: 3.603

4.  Bendamustine and G-CSF support.

Authors:  Osamu Imataki; Shumpei Uchida; Shigeyuki Yokokura; Makiko Uemura; Norimitsu Kadowaki
Journal:  Support Care Cancer       Date:  2018-02-26       Impact factor: 3.603

5.  Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.

Authors:  Romina Sosa; Shuling Li; Julia T Molony; Jiannong Liu; Scott Stryker; Allan J Collins
Journal:  Support Care Cancer       Date:  2017-04-29       Impact factor: 3.603

6.  Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone.

Authors:  Claudio Cerchione; Lucio Catalano; Ilaria Peluso; Davide Nappi; Maria Di Perna; Dalila Salvatore; Ilaria Migliaccio; Marco Picardi; Fabrizio Pane
Journal:  Support Care Cancer       Date:  2016-10-10       Impact factor: 3.603

7.  Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.

Authors:  Claudio Cerchione; Davide Nappi; Maria Di Perna; Irene Zacheo; Anna Emanuele Pareto; Marco Picardi; Lucio Catalano; Fabrizio Pane
Journal:  Case Rep Hematol       Date:  2016-10-27

8.  Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.

Authors:  Claudio Cerchione; Amalia De Renzo; Maria Di Perna; Roberta Della Pepa; Novella Pugliese; Lucio Catalano; Fabrizio Pane; Marco Picardi
Journal:  Support Care Cancer       Date:  2016-11-03       Impact factor: 3.603

9.  A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.

Authors:  Claudio Cerchione; Davide Nappi; Maria Di Perna; Irene Zacheo; Ilaria Migliaccio; Dalila Salvatore; Marco Picardi; Fabrizio Pane; Lucio Catalano
Journal:  Clin Case Rep       Date:  2017-03-08
  9 in total
  6 in total

1.  Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea.

Authors:  Jaekyung Cheon; Hyeon-Su Im; Ho-Jin Shin; Inho Kim; Won Sik Lee; Kyung-Hun Lee; Seong Kyu Park; Min Kyoung Kim; Un Jong Choi; Jung Han Kim; IlKyun Lee; Jae-Cheol Jo
Journal:  Support Care Cancer       Date:  2021-03-08       Impact factor: 3.603

2.  Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin's lymphoma.

Authors:  Lauren Roder; Kelsey Konrardy; Dennis Grauer; Marc Hoffmann
Journal:  Support Care Cancer       Date:  2021-02-17       Impact factor: 3.603

3.  Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors.

Authors:  Ryunosuke Nakagawa; Hiroaki Iwamoto; Tomoyuki Makino; Suguru Kadomoto; Hiroshi Yaegashi; Masashi Iijima; Shohei Kawaguchi; Takahiro Nohara; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Atsushi Mizokami
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

4.  Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.

Authors:  Claudio Cerchione; Davide Nappi; Alessandra Romano; Giovanni Martinelli
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

Review 5.  Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

Authors:  Claudio Cerchione; Davide Nappi; Giovanni Martinelli
Journal:  Support Care Cancer       Date:  2021-05-14       Impact factor: 3.603

6.  Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.

Authors:  Claudio Cerchione; Davide Nappi; Gerardo Musuraca; Alessandro Lucchesi; Ilaria Cimmino; Fabrizio Pane; Amalia De Renzo; Giovanni Martinelli
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.